Current Research Studies
A Phase 2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Crinecerfont in Pediatric Participants 3 Months to <4 Years of Age With Classic Congenital Adrenal Hyperplasia
NBI-74788-CAH2032
What is the goal of the study?
Safety, tolerability, and pharmacokinetics of crinecerfont in participants with classic congenital adrenal hyperplasia who are less than 4 years old
Who can participate in the study?
Please contact the study team listed below to learn more.